Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.07
(0.8%)
CNY 5.07
(0.8%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 662.35 Million CNY | -85.26% |
| 2022 | 3.88 Billion CNY | 114.75% |
| 2021 | 1.8 Billion CNY | 81.92% |
| 2020 | 993.74 Million CNY | 69.06% |
| 2019 | 587.8 Million CNY | 21.3% |
| 2018 | 484.57 Million CNY | 20.99% |
| 2017 | 400.5 Million CNY | 17.37% |
| 2016 | 341.23 Million CNY | 12.6% |
| 2015 | 303.04 Million CNY | 32.99% |
| 2014 | 227.86 Million CNY | 51.76% |
| 2013 | 150.15 Million CNY | 39.92% |
| 2012 | 107.31 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 127.22 Million CNY | 40.87% |
| 2024 Q1 | 90.31 Million CNY | -26.83% |
| 2024 Q3 | 105.31 Million CNY | -14.27% |
| 2023 Q4 | 123.42 Million CNY | -4.53% |
| 2023 Q3 | 129.27 Million CNY | -38.12% |
| 2023 FY | 572.38 Million CNY | -85.26% |
| 2023 Q2 | 208.92 Million CNY | 12.17% |
| 2023 Q1 | 186.25 Million CNY | -80.88% |
| 2022 Q4 | 973.94 Million CNY | 1.9% |
| 2022 Q2 | 906.11 Million CNY | -13.42% |
| 2022 Q1 | 1.04 Billion CNY | 125.89% |
| 2022 FY | 3.88 Billion CNY | 114.75% |
| 2022 Q3 | 955.73 Million CNY | 5.48% |
| 2021 Q4 | 463.28 Million CNY | -5.58% |
| 2021 Q2 | 451.93 Million CNY | 12.44% |
| 2021 Q3 | 490.67 Million CNY | 8.57% |
| 2021 FY | 1.8 Billion CNY | 81.92% |
| 2021 Q1 | 401.93 Million CNY | 37.05% |
| 2020 FY | 993.74 Million CNY | 69.06% |
| 2020 Q3 | 312.99 Million CNY | 14.01% |
| 2020 Q1 | 112.92 Million CNY | -32.58% |
| 2020 Q4 | 293.27 Million CNY | -6.3% |
| 2020 Q2 | 274.54 Million CNY | 143.11% |
| 2019 Q2 | 146.4 Million CNY | 32.35% |
| 2019 Q4 | 167.5 Million CNY | 2.58% |
| 2019 Q1 | 110.61 Million CNY | -24.24% |
| 2019 FY | 587.8 Million CNY | 21.3% |
| 2019 Q3 | 163.28 Million CNY | 11.53% |
| 2018 Q1 | 88.35 Million CNY | -23.7% |
| 2018 FY | 484.57 Million CNY | 20.99% |
| 2018 Q4 | 146.01 Million CNY | 12.16% |
| 2018 Q3 | 130.18 Million CNY | 8.47% |
| 2018 Q2 | 120.01 Million CNY | 35.84% |
| 2017 FY | 400.5 Million CNY | 17.37% |
| 2017 Q3 | 104.98 Million CNY | -1.32% |
| 2017 Q4 | 115.8 Million CNY | 10.31% |
| 2017 Q1 | 73.34 Million CNY | -28.2% |
| 2017 Q2 | 106.38 Million CNY | 45.04% |
| 2016 Q3 | 85.42 Million CNY | -4.13% |
| 2016 FY | 341.23 Million CNY | 12.6% |
| 2016 Q2 | 89.1 Million CNY | 38.05% |
| 2016 Q1 | 64.54 Million CNY | 0.0% |
| 2016 Q4 | 102.15 Million CNY | 19.57% |
| 2015 FY | 303.04 Million CNY | 32.99% |
| 2014 FY | 227.86 Million CNY | 51.76% |
| 2013 FY | 150.15 Million CNY | 39.92% |
| 2012 FY | 107.31 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.15 Billion CNY | 84.048% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.72 Billion CNY | 75.671% |
| Dirui Industrial Co.,Ltd. | 669.29 Million CNY | 1.038% |
| Beijing Strong Biotechnologies, Inc. | 1.3 Billion CNY | 49.064% |
| Medicalsystem Biotechnology Co., Ltd. | 834.37 Million CNY | 20.617% |
| Maccura Biotechnology Co.Ltd | 1.51 Billion CNY | 56.181% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.72 Billion CNY | 61.592% |
| BGI Genomics Co., Ltd. | 2.17 Billion CNY | 69.485% |
| Amoy Diagnostics Co., Ltd. | 871.54 Million CNY | 24.002% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 329.31 Million CNY | -101.131% |